PTC Therapeutics, Inc.
PTCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,468,786 | $2,062,546 | $2,737,882 | $2,806,676 |
| - Cash | $779,709 | $594,001 | $279,834 | $189,718 |
| + Debt | $2,471,072 | $2,229,123 | $1,461,513 | $1,269,364 |
| Enterprise Value | $5,160,149 | $3,697,668 | $3,919,561 | $3,886,322 |
| Revenue | $806,780 | $937,822 | $698,801 | $538,593 |
| % Growth | -14% | 34.2% | 29.7% | – |
| Gross Profit | $749,382 | $872,336 | $654,123 | $506,265 |
| % Margin | 92.9% | 93% | 93.6% | 94% |
| EBITDA | -$120,463 | -$330,340 | -$367,780 | -$368,184 |
| % Margin | -14.9% | -35.2% | -52.6% | -68.4% |
| Net Income | -$363,295 | -$626,604 | -$559,017 | -$523,901 |
| % Margin | -45% | -66.8% | -80% | -97.3% |
| EPS Diluted | -4.73 | -8.37 | -7.79 | -7.43 |
| % Growth | 43.5% | -7.4% | -4.8% | – |
| Operating Cash Flow | -$107,688 | -$158,418 | -$356,654 | -$251,332 |
| Capital Expenditures | -$74,249 | -$120,619 | -$152,460 | -$85,331 |
| Free Cash Flow | -$181,937 | -$279,037 | -$509,114 | -$336,663 |